ArticleFrontiers in immunology2025
Peripheral blood tRNA-derived fragments as novel noninvasive biomarkers for diagnosis and prognostic stratification in multiple myeloma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transfer RNA-derived small RNAs (tsRNAs) have recently emerged as critical regulators in cancer biology; yet their expression profiles and clinical relevance in multiple myeloma (MM) remain poorly defined. Methods: High-throughput sequencing was performed to comprehensively characterize tsRNA expression profiles in peripheral blood mononuclear cells (PBMCs) from 22 newly diagnosed MM patients and 19 healthy controls. Shared target genes were predicted by integrating miRanda and TargetScan, and a tsRNA-mRNA interaction network was constructed; GO and KEGG functional enrichment analyses were also performed. The discriminative performance of candidate biomarkers was evaluated using receiver operating characteristic (ROC) curves, and the associations between candidate tsRNAs and clinical parameters were further examined by correlation analyses. Results: A total of 148 significantly upregulated and 63 downregulated tsRNAs were identified. Among them, Other-1_19-tRNA-SeC-TCA-1 and Other-36_54-tRNA-Met-CAT-2-M4 exhibited excellent diagnostic performance, with areas under the ROC curve (AUCs) of 0.9557 and 0.9773, respectively. Functional analyses revealed that differentially expressed tsRNAs were primarily involved in regulating signaling pathways such as TGF-β, PI3K-Akt, and AMPK, and were closely associated with thyroid hormone metabolism. Elevated expression of Other-22_52-tRNA-Gly-GCC-1-M3 was significantly correlated with renal insufficiency (p < 0.05), suggesting its potential as a novel biomarker for assessing renal injury risk. The tsRNA-mRNA regulatory network comprised 11,141 interaction edges and exhibited a power-law topology, with the hub gene SRSF10 mediating coordinated regulation across multiple pathways. Conclusions: Our findings reveal a distinct imbalance in tsRNA expression in MM, indicating that specific tsRNA fragments contribute to disease progression and renal injury through multifaceted signaling networks, thereby providing novel molecular insights for early diagnosis and risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.